Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-D: Anticoagulation Strategies in Dialysis Patients with Atrial Fibrillation
NCT03987711Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of warfarin in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms), sponsored by Unity Health Toronto. Primary endpoints: Recruitment of the target population within 2 years and Randomized participants remaining in the trial and on allocated treatment at 26 weeks. Started Dec 2019; status: completed.
02
Drugs
warfarin
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT03987711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987711.